Zhejiang Wecome Pharmaceutical Co Ltd

Zhejiang Wecome Pharmaceutical Co Ltd has a market price of 32.51 CNY per share, with a market capitalization of 4.71 billion CNY. The company's price-to-book ratio is 5.17, and its price-to-tangible-book ratio is also 5.17, indicating that the market is valuing the company's equity at a premium relative to its book value. The enterprise value to EBITDA ratio is negative at -24.23, reflecting the company's current operating losses. The enterprise value to revenue ratio is 21.63, suggesting that the company is trading at a high multiple of its revenue.

The company's profitability metrics are concerning. The return on equity is -24.97%, and the return on assets is -18.17%, both of which are significantly below the industry median for pharmaceutical companies. The company reported a net loss of 227.34 million CNY and an operating loss of 201.09 million CNY, indicating a challenging operating environment. The gross profit margin is 17.86%, which is below the industry average, suggesting that the company is struggling to maintain profitability despite its revenue of 225.27 million CNY.

Zhejiang Wecome Pharmaceutical Co Ltd's revenue is primarily concentrated in the domestic market, with no significant international exposure disclosed in the available data. The company's geographic and segmental breakdown is not detailed in the provided data, but the lack of international diversification may increase its exposure to domestic economic and regulatory risks.

The company's growth trajectory is mixed. While it has a revenue of 225.27 million CNY, the operating and net losses suggest that the company is not currently generating sustainable profits. The free cash flow is negative at -262.45 million CNY, and the capital expenditure is -67.17 million CNY, indicating that the company is investing in its operations but is not generating sufficient cash to support these investments. The outlook for the current fiscal year is uncertain, with no clear direction provided in the available data.

The company's risk profile is moderate. The liquidity risk is rated as medium, and the dilution risk is low. The key financial flag is that the company has negative net cash after subtracting total debt, which could impact its ability to meet short-term obligations. The debt-to-equity ratio is 0.18, indicating a relatively low level of leverage. The current ratio is 2.07, suggesting that the company has sufficient current assets to cover its current liabilities.

Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The company's financial performance and risk profile suggest that it is in a challenging phase, with the need to address its operating losses and improve its cash flow generation.